Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept Corporation is set to launch Ceplene (histamine dihydrochloride) in the UK on 20 April, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland.
Subscribe to our email newsletter
Ceplene is approved in the EU for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission. The launch is being conducted by Meda, as part of an exclusive commercialisation agreement for Ceplene signed by the two companies in January 2010.
EpiCept said that in support of the commercial launch for Ceplene, Meda is expected to be holding a Satellite Symposium session on Tuesday, April 20, 2010 at the aforementioned scientific meeting. The session, entitled ‘Maintaining Remission in AML – The Challenge,’ will be co-chaired by Alan Burnett and Jonathen Kell.
Jack Talley, president and CEO of EpiCept, said: “We are very pleased that Ceplene will soon be readily available to clinicians in the UK and that patients will be able to reap the benefits of the only immunomodulator proven to show a clear benefit in prolonging leukemia-free survival and preventing relapse in AML patients. We look forward to working closely with Meda for the drug’s next expected launch in Germany, and ultimately throughout Europe.”